NYSE · HAE
Haemonetics Corporation
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
Loading market information…
NYSE · CON · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Concentra Group Holdings Parent, Inc.’s forward annual dividend is $0.25 per share, paid quarterly. The forward yield is 0.61% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Concentra Group Holdings Parent, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.44. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Concentra Group Holdings Parent, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 7, 2025 | $0.32+3.23% vs estimate | $500.75M+0.95% vs estimate |
|---|
| Q4 2024 | Mar 3, 2025 | $0.17+6.25% vs estimate | $465.04M-4.43% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | $0.37+2.78% vs estimate | $489.64M-0.6% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $41.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
$31.49$0.00 (0.0%)
Catalyst Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.29% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$13.59+$0.27 (+2.03%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$124.34+$2.16 (+1.77%)
Addus HomeCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
$48.75+$0.96 (+2.01%)
Prestige Consumer Healthcare Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.41% below the high.
